Dr Shitara talks to ecancer at ASCO 2025 about the international phase 3 DESTINY-Gastric04 clinical trial.

The study found that second-line treatment with trastuzumab deruxtecan can help people with advanced HER2-positive gastric cancers that have grown during first-line treatment live around 3 months longer.

These findings further support the use of trastuzumab deruxtecan in the second-line setting for these patients.

People with metastatic gastric cancer often have a poor prognosis, with a 5-year survival rate ranging from 5% to 10%. About 5% to17% of these cancers are HER2-positive.